Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Official Calls for Use of Academic Data in Drug Submissions
April 26, 2016
- Quakes Injure 3, Cause Property Damage for 22 Companies: JPMA Survey
April 20, 2016
- JPMA Sets Up Taskforce for Russia, Brazil, Mexico, Turkey
April 18, 2016
- Contract Sales Reps in Japan Likely to Increase to 6,000 in 2021: Industry Group
April 15, 2016
- Japan at a Crossroads as Investment Destination, World’s Eyes Riveted on Govt’s Signals: PhRMA Local Chief
April 13, 2016
- EFPIA Japan Chief to Call for “Real Dialogue” at Today’s Public-Private Policy Confab
April 12, 2016
- Asian Industry Groups Agree to Continue Efforts to Improve Access to Innovative Medicines in Asia
April 11, 2016
- Front-Loaded Price Cuts Necessary for Drugs Like Opdivo: JMA’s Nakagawa
April 7, 2016
- Japan Pharma Groups Step Up Lobbing Campaigns to Skirt Further Drug Cost Cuts
April 7, 2016
- Generic Use Rate at 56.1% in October-December 2015: JGA
April 1, 2016
- JPMA Issues Notification Urging Member Companies to Strengthen Internal Ad Review Systems
March 25, 2016
- FPMAJ Braced for Thorny Path Ahead Even If Sales Tax Postponed, Revenue Falls Would Weigh on Industry: Chief
March 18, 2016
- Discuss Role of Drugs in Overall Social Security System: Full Interview with FPMAJ Pricing Affairs Chief
March 18, 2016
- “Huge-Seller” Re-Pricing Eroding Predictability of Japanese System: FPMAJ’s Kamoya
March 10, 2016
- PhRMA Japan Committee Sets Out Guiding Principles for MSLs
February 26, 2016
- FY2016 Reimbursement Policy Reform “Tough” on Industry: JPMA
February 19, 2016
- Top MHLW Bureaucrat Says 80% Generic Share “Achievable”
February 16, 2016
- Former JMA Pres. Eitaka Tsuboi Dies at 86
February 15, 2016
- EFPIA Japan Lays Out Basic Principles on MSL Activities
February 4, 2016
- Japanese Pharma Market to Shrink 30% over 10 Years with Annual Revisions: New PhRMA Japan Chief
January 22, 2016
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…